脂质体两性霉素B成功治疗巴西利什曼原虫皮肤利什曼病。
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
作者信息
Brown M, Noursadeghi M, Boyle J, Davidson R N
机构信息
Department of Infection & Tropical Medicine, Northwick Park Hospital, Harrow, UK.
出版信息
Br J Dermatol. 2005 Jul;153(1):203-5. doi: 10.1111/j.1365-2133.2005.06670.x.
Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.
目前用于治疗由巴西利什曼原虫（维安纳亚属）引起的新大陆皮肤利什曼病（CL）的全身治疗方法并不令人满意。脂质体两性霉素B已广泛用于治疗内脏利什曼病，但用于CL治疗的情况较少，且尚未描述适合CL的治疗方案。我们成功治疗了一名在伯利兹感染多个巴西利什曼原虫CL病灶的患者。脂质体两性霉素B（安必素）作为住院患者给予我们的患者，每日剂量为3 mg kg⁻¹，共7天，然后作为门诊患者，每周两次，每次3 mg kg⁻¹，持续三周，总计40 mg kg⁻¹。脂质体两性霉素为新大陆CL的全身治疗提供了一种耐受性良好的替代五价锑或两性霉素B脱氧胆酸盐的药物。
Zotero 插件